UniQure plunges as Huntington's trial data disappoints investors

A medical laboratory technician works in a research lab in South Africa, February 14, 2025.

A medical laboratory technician works in a research lab in South Africa, February 14, 2025. (REUTERS/Ihsaan Haffejee)


1 photo
Save Story

Estimated read time: 1-2 minutes

Sept 29 — UniQure said its gene therapy for Huntington's disease fell short โ€‹of the goal of slowing disease progression significantly after four years, sending its US-listed shares plummeting 40% on Tuesday.

The Dutch company โ€Œearlier this month applied for US approval of the treatment, AMT-130, after the FDA ended an โ eight-month-long standoff over the adequacy โ€‹of data.

Its application was based on โ a 36-month analysis of the trial, in which the therapy slowed โ€Œprogression of the brain โ€Œdisorder by 75%.

Walid Abi-Saab, uniQure's chief medical officer, said it โ is difficult to speculate on whether the โ Food and Drug Administration will reconsider the application with the new data.

Tuesday's data showed that AMT-130 slowed disease progression by 44% in 12 high-dose patients at 48 months, compared with an updated control group. But the result did not reach statistical significance, the company โ€Œsaid.

UNIQURE CITES CHANGES TO CONTROL GROUP

UniQure said control-group โ€‹patients who discontinued follow-up appeared to experience faster disease progression than those who remained, meaning the control data may have understated AMT-130's potential benefit.

"We do think that, beyond three years, the data is really suffering from this survivor bias," Abi-Saab said.

The therapy's effect on disease progression was measured on the cUHDRS scale, a composite measure of โ€‹cognitive, motor and functional decline.

It showed a 61% slowing at four years on โ€ŒTFC, a narrower โ€Œfunctional โ measure that assesses a patient's ability to perform everyday activities, such as working, household tasks and self-care.

Guggenheim analyst Debjit Chattopadhyay said a steady measure on TFC counterbalances the lower reading on the cUHDRS scale.

Huntington's disease is a โ€Œrare inherited brain disorder โ€‹that causes movement difficulties and triggers โ€Œbehavioral changes and cognitive โ decline. No approved โ€‹drugs exist that help slow progression.

(Reporting by Christy Santhosh in Bengaluru; Editing by โ€‹Sahal Muhammed)

Photos

Most recent Lifestyle stories

Related topics

KSL.com Beyond Series
KSL.com Beyond Business

KSL Weather Forecast

KSL Weather Forecast
Play button